Create a narrative

Exact Sciences Community

NasdaqCM:EXAS Community

1 Narratives written by author
0 Comments on narratives written by author
46 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 26 Analysts

Cologuard Plus And Oncodetect Will Improve Cancer Screening Outcomes

Key Takeaways Cologuard Plus and rescreening efforts are key drivers of revenue growth, bolstered by payer coverage and an increasing pool of eligible individuals. ExactNexus technology enhances efficiency and customer experience, strengthening Exact Sciences' position in precision oncology and improving future earnings.

US$66.85

FV

14.8% undervalued

11.71%

Revenue growth p.a.

0

0

28

4 days ago